We are live on
!
Find out more
CS
Candriam SCA Portfolio holdings
AUM
$19.3B
1-Year Est. Return
39.18%
This Fund
S&P 500
This Quarter
Est. Return
+8.76%
1 Year Est. Return
+39.18%
3 Year Est. Return
+109.85%
5 Year Est. Return
+149.31%
10 Year Est. Return
+617.16%
AUM
$13.8B
AUM Growth
-$581M
(-4%)
Cap. Flow
-$2.79B
Cap. Flow
% of AUM
-20.16%
Top 10 Holdings %
Top 10 Hldgs %
25.18%
Holding
905
New
29
Increased
148
Reduced
448
Closed
194
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Lam Research
LRCX
|
+$66.4M |
| 2 |
Valero Energy
VLO
|
+$28.9M |
| 3 |
SLB Ltd
SLB
|
+$24.8M |
| 4 |
BNY
Bank of New York Mellon
BNY
|
+$22.6M |
| 5 |
PepsiCo
PEP
|
+$20.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$182M |
| 2 |
Apple
AAPL
|
+$148M |
| 3 |
Alphabet (Google) Class A
GOOGL
|
+$90.9M |
| 4 |
Amgen
AMGN
|
+$72.1M |
| 5 |
Tesla
TSLA
|
+$66.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 31.26% |
| 2 | Technology | 28.78% |
| 3 | Financials | 8.15% |
| 4 | Consumer Discretionary | 7.54% |
| 5 | Industrials | 7.28% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
301
Zimmer Biomet
ZBH
$17.8B
| $6.21M | 0.04% |
42,631
-23,708
| -36% | -$3.22M |
|
302
American Tower
AMT
$77.7B
| $6.1M | 0.04% |
31,453
-29,907
| -49% | -$5.85M |
|
303
Kraft Heinz
KHC
$31.1B
| $6.05M | 0.04% |
170,404
-78,529
| -32% | -$3.02M |
|
304
Trex
TREX
$4.57B
| $6.01M | 0.04% |
91,711
| – | – |
|
|
GTLS
305
DELISTED
Chart Industries
GTLS
| $6M | 0.04% |
37,537
-4,757
| -11% | -$608K |
|
306
General Motors
GM
$78.7B
| $5.94M | 0.04% |
154,153
-1,555
| -1% | -$53.8K |
|
307
Nordson
NDSN
$16.6B
| $5.9M | 0.04% |
23,783
+16,640
| +233% | +$3.71M |
|
308
O'Reilly Automotive
ORLY
$75.1B
| $5.89M | 0.04% |
92,505
+435
| +0.5% | +$26.6K |
|
|
RAPT
309
DELISTED
RAPT Therapeutics
RAPT
| $5.86M | 0.04% |
39,158
-2,142
| -5% | -$334K |
|
310
Sempra
SRE
$59.7B
| $5.77M | 0.04% |
79,282
-25,412
| -24% | -$1.91M |
|
311
Campbell Soup
CPB
$6.67B
| $5.77M | 0.04% |
126,192
+80,401
| +176% | +$4.15M |
|
312
Marathon Petroleum
MPC
$91.2B
| $5.74M | 0.04% |
49,199
+2,274
| +5% | +$264K |
|
313
IDEX
IEX
$16.6B
| $5.72M | 0.04% |
26,573
-31,551
| -54% | -$6.63M |
|
314
MINISO
MNSO
$3.72B
| $5.7M | 0.04% |
207,000
+35,000
| +20% | +$584K |
|
315
Take-Two Interactive
TTWO
$45.3B
| $5.66M | 0.04% |
38,494
-932
| -2% | -$122K |
|
316
Chipotle Mexican Grill
CMG
$42.6B
| $5.54M | 0.04% |
129,600
-20,200
| -13% | -$799K |
|
317
MetLife
MET
$61.2B
| $5.42M | 0.04% |
95,902
-326,386
| -77% | -$18.1M |
|
318
Moody's
MCO
$84.2B
| $5.41M | 0.04% |
15,550
-25,535
| -62% | -$8.09M |
|
319
Harley-Davidson
HOG
$2.61B
| $5.4M | 0.04% |
153,489
-75,930
| -33% | -$2.65M |
|
|
SCHW
320
Charles Schwab
SCHW
$181B
| $5.4M | 0.04% |
95,245
-120,339
| -56% | -$6.3M |
|
321
Visteon
VC
$2.82B
| $5.39M | 0.04% |
37,552
-49,773
| -57% | -$7.09M |
|
|
AKRO
322
DELISTED
Akero Therapeutics
AKRO
| $5.37M | 0.04% |
115,000
+10,000
| +10% | +$458K |
|
323
Dollar General
DG
$27.2B
| $5.34M | 0.04% |
31,430
-84,059
| -73% | -$16.6M |
|
324
Regency Centers
REG
$15.1B
| $5.21M | 0.04% |
84,285
-19,512
| -19% | -$1.16M |
|
325
Exelon
EXC
$48.2B
| $5.13M | 0.04% |
125,815
-198,957
| -61% | -$8.22M |
|
Similar funds
PCM
A
MGP
LF
SOMRS
BPA
MIM
Candriam SCA's Q2 2023 Portfolio in Review
As of Q2 2023, Candriam SCA held 905 positions worth $13.8B, down 4% from $14.4B the previous quarter. Its ten largest holdings account for 25% of the portfolio.
Candriam SCA withdrew a net $2.79B in Q2 2023, closing 194 positions and reducing 448 holdings. Its most notable exit was Thomson Reuters, an estimated $19.8M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 31% of assets, up from 31% a quarter earlier, followed by Technology and Financials.
Against the trend, Candriam SCA opened a new position in Vir Biotechnology worth $8.7M.
- Candriam SCA's largest Q2 2023 buy was Vir Biotechnology: 354,645 shares worth $8.7M.
- Candriam SCA added most to Lam Research in Q2 2023, an estimated $66.4M increase.
- Candriam SCA's biggest Q2 2023 reduction was Microsoft, cutting an estimated $182M.
- Candriam SCA fully exited Thomson Reuters in Q2 2023, selling an estimated $19.8M.
- Candriam SCA's ten largest holdings make up 25% of its $13.8B portfolio in Q2 2023.
- Candriam SCA opened 29 new positions and closed 194 in Q2 2023.
- Candriam SCA's portfolio value fell 4% quarter-over-quarter to $13.8B.
Based on Candriam SCA's 13F filing for Q2 2023, filed 8 Aug 2023.